{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T22:10:24Z","timestamp":1778191824870,"version":"3.51.4"},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1097\/inf.0000000000001022","type":"journal-article","created":{"date-parts":[[2015,12,10]],"date-time":"2015-12-10T22:12:51Z","timestamp":1449785571000},"page":"414-421","source":"Crossref","is-referenced-by-count":29,"title":["Pharmacokinetics and Dosing of Levofloxacin in Children Treated for Active or Latent Multidrug-resistant Tuberculosis, Federated States of Micronesia and Republic of the Marshall Islands"],"prefix":"10.1097","volume":"35","author":[{"given":"Sundari R.","family":"Mase","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John A.","family":"Jereb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Gonzalez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatma","family":"Martin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles L.","family":"Daley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dorina","family":"Fred","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ann M.","family":"Loeffler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lakshmy R.","family":"Menon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sapna","family":"Bamrah Morris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Brostrom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Terence","family":"Chorba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles A.","family":"Peloquin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"issue":"suppl 7A","key":"R1-13-20210202","doi-asserted-by":"crossref","first-page":"14S","DOI":"10.1016\/j.amjmed.2005.05.009","article-title":"Appropriate antibiotic treatment of genitourinary infections in hospitalized patients.","volume":"118","author":"Liu","year":"2005","journal-title":"Am J Med"},{"key":"R2-13-20210202","doi-asserted-by":"crossref","first-page":"380","DOI":"10.3201\/eid1103.040819","article-title":"Antimicrobial drug prescribing for pneumonia in ambulatory care.","volume":"11","author":"MacDougall","year":"2005","journal-title":"Emerg Infect Dis"},{"key":"R3-13-20210202","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1128\/AAC.01036-07","article-title":"Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis.","volume":"52","author":"Peloquin","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"R5-13-20210202","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1128\/AAC.00414-06","article-title":"Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy.","volume":"51","author":"Shandil","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"R6-13-20210202","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2165\/00003088-199732020-00002","article-title":"The clinical pharmacokinetics of levofloxacin.","volume":"32","author":"Fish","year":"1997","journal-title":"Clin Pharmacokinet"},{"key":"R7-13-20210202","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1177\/0091270004271944","article-title":"Levofloxacin pharmacokinetics in children.","volume":"45","author":"Chien","year":"2005","journal-title":"J Clin Pharmacol"},{"key":"R8-13-20210202","doi-asserted-by":"crossref","first-page":"2948","DOI":"10.1128\/AAC.02755-13","article-title":"Pharmacokinetics of ofloxacin and levofloxacin for prevention and treatment of multidrug-resistant tuberculosis in children.","volume":"58","author":"Thee","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"R9-13-20210202","doi-asserted-by":"crossref","first-page":"912","DOI":"10.5588\/ijtld.13.0028","article-title":"Treatment for latent tuberculosis infection in contacts to multidrug-resistant tuberculosisFederated States of Micronesia, 2009-2012.","volume":"18","author":"Bamrah","year":"2014","journal-title":"Int J Tuberc Lung Dis"},{"key":"R10-13-20210202","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/978-1-62703-050-2_16","article-title":"Non-compartmental analysis.","volume":"929","author":"Gabrielsson","year":"2012","journal-title":"Methods Mol Biol"},{"key":"R11-13-20210202","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.cmpb.2003.11.003","article-title":"Perl-speaks-NONMEM (PsN)a Perl module for NONMEM related programming.","volume":"75","author":"Lindbom","year":"2004","journal-title":"Comput Methods Programs Biomed"},{"key":"R12-13-20210202","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.cmpb.2010.04.018","article-title":"Pirana and PCluster: a modeling environment and cluster infrastructure for NONMEM.","volume":"101","author":"Keizer","year":"2011","journal-title":"Comput Methods Programs Biomed"},{"key":"R13-13-20210202","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1208\/s12248-011-9255-z","article-title":"Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models.","volume":"13","author":"Bergstrand","year":"2011","journal-title":"AAPS J"},{"key":"R15-13-20210202","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0169-2607(98)00067-4","article-title":"Xposean S-PLUS based population pharmacokineticpharmacodynamic model building aid for NONMEM.","volume":"58","author":"Jonsson","year":"1999","journal-title":"Comput Methods Programs Biomed"},{"key":"R16-13-20210202","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1128\/AAC.00667-09","article-title":"Pharmacometrics-based dose selection of levofloxacin as a treatment for postexposure inhalational anthrax in children.","volume":"54","author":"Li","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"R18-13-20210202","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1056\/NEJM199309093291108","article-title":"Treatment of multidrug-resistant tuberculosis.","volume":"329","author":"Iseman","year":"1993","journal-title":"N Engl J Med"},{"key":"R19-13-20210202","first-page":"19","article-title":"Treatment of latent tuberculosis in persons at risk for multidrug-resistant tuberculosis: systematic review.","volume":"10","author":"Fraser","year":"2006","journal-title":"Int J Tuberc Lung Dis"},{"key":"R20-13-20210202","doi-asserted-by":"crossref","first-page":"144","DOI":"10.4103\/0022-3859.32220","article-title":"Ofloxacin-induced reversible arthropathy in a child.","volume":"53","author":"Dolui","year":"2007","journal-title":"J Postgrad Med"},{"key":"R22-13-20210202","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1177\/030098589202900307","article-title":"Ultrastructural changes in articular cartilages of immature beagle dogs dosed with difloxacin, a fluoroquinolone.","volume":"29","author":"Burkhardt","year":"1992","journal-title":"Vet Pathol"},{"key":"R23-13-20210202","first-page":"97","article-title":"Fluoroquinolone use in children: resistance and safety implications. Contemp.","volume":"20","author":"Blumer","year":"2003","journal-title":"Pediatr"},{"key":"R24-13-20210202","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1586\/14787210.3.6.995","article-title":"Drug-resistant tuberculosis: controversies and challenges in pediatrics.","volume":"3","author":"Smith","year":"2005","journal-title":"Expert Rev Anti Infect Ther"},{"key":"R26-13-20210202","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1128\/CMR.00047-06","article-title":"Setting and revising antibacterial susceptibility breakpoints.","volume":"20","author":"Turnidge","year":"2007","journal-title":"Clin Microbiol Rev"},{"key":"R27-13-20210202","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1093\/jac\/dkq091","article-title":"Wild-type MIC distributions of four fluoroquinolones active against Mycobacterium tuberculosis in relation to current critical concentrations and available pharmacokinetic and pharmacodynamic data.","volume":"65","author":"Angeby","year":"2010","journal-title":"J Antimicrob Chemother"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000001022","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T01:09:38Z","timestamp":1620954578000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006454-201604000-00013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":22,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000001022","relation":{},"ISSN":["0891-3668"],"issn-type":[{"value":"0891-3668","type":"print"}],"subject":[],"published":{"date-parts":[[2016,4]]}}}